Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 12% of the time (422 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-04-03. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subjects withsubjects whoto determinediagnosisschizophrenia
  Phrases that lowered it: evaluate theto evaluateefficacyadolescentsat screening
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports marked serious: 49.6% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Sponsor's past termination rate: 8.4% (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 4.6% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Phase: 3 (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 18 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 155 (lowers risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design
• Minimum age: 13 (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia NCT03238326 · started 2017 · scored riskier than 21% of active trials completed
• Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia NCT02411695 · started 2015 · scored riskier than 12% of active trials completed
• Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia NCT01668797 · started 2012 · scored riskier than 23% of active trials completed
• Brexpiprazole in Patients With Acute Schizophrenia NCT01810380 · started 2013 · scored riskier than 24% of active trials completed
• Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia NCT02013622 · started 2013 · scored riskier than 14% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.